- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Volitionrx Ltd (VNRX)
The Volitionrx Ltd share price today is 1.275, view NYSE VNRX stock exchange data. Track the latest Volitionrx Ltd share price with real-time updates on VNRX stock performance including market cap, day range, 52-week range and dividend yield. Access VNRX charts, earnings dates and analyst estimates to support your investment decisions.
1.275
-0.125(-8.93%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.250
1.390
52 wk Range
1.170
16.000
VNRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.2501.390
52 wk Range
1.17016.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VNRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
16.966
Upside
+1,230.67%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Volitionrx Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Volitionrx Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 16.966
(+1,230.67% Upside)
Volitionrx Ltd Earnings Call Summary for Q1/2026
- Q1 2026 revenue surged 300% YoY to $1.0M, driven by deferred revenue recognition from Nu.Q Vet agreement with Heska.
- EPS of -$0.97 dramatically missed forecast of -$0.04, representing a -2,325% surprise; stock fell 7.05% to $2.02 in premarket trading.
- Operating expenses rose 8.6% to $6.3M due to severance costs and higher R&D spending; company raised $7.3M in capital during quarter.
- No specific 2026 revenue guidance provided, citing unpredictable revenue streams; management focused on cost reduction and operational efficiency.
- Completed Nu.Q Vet cancer test validation described as 'world first,' enabling full automation and integration with existing diagnostic platforms.
Last Updated: 15-05-2026, 07:06 pm
Read Full TranscriptEarnings
Latest Release
15-05-2026
EPS / Forecast
-0.97 / -0.04
Revenue / Forecast
990K / 2.05M
Compare VNRX to Peers and Sector
Metrics to compare | VNRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVNRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −48.9x | −0.4x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price/Book | −0.3x | 1.0x | 2.6x | |
Price / LTM Sales | 4.3x | 11.1x | 3.0x | |
Upside (Analyst Target) | - | 1.8% | 49.7% | |
Fair Value Upside | Unlock | −30.7% | 7.3% | Unlock |
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Volitionrx Ltd (VNRX) Share Price Today?
The Volitionrx Ltd share price today is 1.275.
What is the current Volitionrx Ltd (VNRX) share price and day range?
As of 08-07-2026, the Volitionrx Ltd share price is 1.275, with a previous close of 1.400. The share price has ranged from 1.250 to 1.390 today, while the 52-week range spans from 1.170 to 16.000.
What Is the Volitionrx Ltd Market Cap?
As of today, Volitionrx Ltd market cap is 10.620M.
What Is the Volitionrx Ltd (VNRX) Share Price Target?
The average 12-month share price target for Volitionrx Ltd is 16.966, with a high estimate of 24 and a low estimate of 4. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +1,230.67% Upside potential.
What Is Volitionrx Ltd's Earnings Per Share (TTM)?
The Volitionrx Ltd EPS (TTM) is -4.201.
When Is the Next Volitionrx Ltd Earnings Date?
Volitionrx Ltd will release its next earnings report on 19-08-2026.
From a Technical Analysis Perspective, Is VNRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Volitionrx Ltd Trade On?
Volitionrx Ltd is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Volitionrx Ltd?
The stock symbol for Volitionrx Ltd is "VNRX."
How Many Times Has Volitionrx Ltd Stock Split?
Volitionrx Ltd has split 1 times.
How Many Employees Does Volitionrx Ltd Have?
Volitionrx Ltd has 67 employees.
What Is the VNRX Premarket Price?
VNRX's last pre-market stock price is 1.390. The pre-market share volume is 260.000, and the stock has changed by -0.010, or -0.710%.
What Is the VNRX After Hours Price?
VNRX's last after hours stock price is 1.380, the stock has changed by -0.020, or -1.430%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.